Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A rolling phenotype in Crohn's disease.

James Irwin1,2,3, Emma Ferguson1,3, Lisa A Simms1

  • 1Inflammatory Bowel Diseases Research Group, QIMR Berghofer Medical Research Institute, Brisbane, Australia.

Plos One
|April 7, 2017
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk of Lymphoma Associated With Biologics and Immunosuppressants in Inflammatory Bowel Disease Patients: A Nationwide Nested Case-Control Study.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Intra-arterial tenecteplase for acute stroke after successful endovascular therapy: the ANGEL-TNK randomized clinical trial.

CJEM·2026
Same author

Surveillance Outcomes in an Australian Cohort Undergoing Piecemeal Polypectomy for Conventional Adenomas and Serrated Lesions.

Digestive diseases and sciences·2026
Same author

Rapid detection and quantification of the fastidious pathogen Streptococcus pneumoniae directly from whole blood using InfectID-BSI: A multiplex qPCR test to augment clinical acumen in sepsis.

Journal of critical care·2026
Same author

Comparative risk of serious infection in patients with ulcerative colitis treated with JAK inhibitors.

Journal of Crohn's & colitis·2026
Same author

Serious Infection in Inflammatory Bowel Diseases Patients Treated With Vedolizumab, Ustekinumab, Janus Kinase Inhibitors, Anti-Tumor Necrosis Factor or Aminosalicylates.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026

The rolling phenotype model for Crohn's disease shows 70% of patients maintain stable, less severe disease over time, unlike the Montreal classification which suggests continuous progression.

Area of Science:

  • Gastroenterology and Hepatology
  • Inflammatory Bowel Disease Research
  • Clinical Epidemiology

Background:

  • The Montreal classification categorizes Crohn's disease (CD) behavior, focusing on disease progression towards stricturing and penetrating complications.
  • Clinical observations suggest CD complications can fluctuate, with potential for both worsening and improvement over time.

Purpose of the Study:

  • To introduce and validate the 'rolling phenotype' as an alternative model for describing the long-term course of Crohn's disease complications.
  • To compare the insights provided by the rolling phenotype model against the traditional cumulative Montreal classification.

Main Methods:

  • A retrospective analysis of 305 Crohn's disease patients with a minimum 5-year follow-up was conducted.
  • A 'rolling phenotype' was defined based on complications observed in the preceding three years at each time point.

Related Experiment Videos

  • Phenotypes (B1, B2, B3, B23) were assessed, and their progression under the rolling phenotype model was compared to the cumulative Montreal phenotype.

    • Main Results:

    • Longitudinal analysis using the rolling phenotype revealed stable proportions: 70% B1 (inflammatory), 20% B2 (stricturing), 5% B3 (penetrating), and 5% B23 (penetrating and stenotic).
    • These proportions remained consistent regardless of the patient's initial disease phenotype.
    • In contrast, the cumulative Montreal phenotype showed a progression towards more severe disease states over a 10-year period.

    Conclusions:

    • The rolling phenotype model offers a dynamic perspective on the burden of intra-abdominal complications in Crohn's disease.
    • This model indicates that a significant majority (70%) of patients experience sustained freedom from severe complications for over three years.